These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
101 related items for PubMed ID: 9133469
21. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I. Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506 [Abstract] [Full Text] [Related]
22. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group. Transplantation; 2001 Sep 15; 72(5):839-45. PubMed ID: 11571447 [Abstract] [Full Text] [Related]
23. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806 [Abstract] [Full Text] [Related]
24. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function. Cohen DJ, Benvenisty AI, Cianci J, Hardy MA. Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):19-27. PubMed ID: 2510507 [Abstract] [Full Text] [Related]
25. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A. Paediatr Drugs; 2003 Nov 15; 5(10):699-716. PubMed ID: 14510627 [Abstract] [Full Text] [Related]
27. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K. Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888 [Abstract] [Full Text] [Related]
28. Immunosuppression in live-related donor renal transplantation. Iman A, Rao M, Juneja R, Jacob CK. Natl Med J India; 2001 Dec 27; 14(2):75-80. PubMed ID: 11396322 [Abstract] [Full Text] [Related]
29. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C, Vasquez AR, Halloran P. Transplantation; 2001 Sep 15; 72(5):845-50. PubMed ID: 11571448 [Abstract] [Full Text] [Related]
30. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC. Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960 [Abstract] [Full Text] [Related]
31. CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo. Nachbaur D, Niederwieser D, Aichinger G, Aulitzky W, Tilg H, Eibl B, König P, Gattringer C, Majdic O, Stockinger H, Margreiter R, Oberhuber G, Födinger AM, Schwaighofer H, Huber C. Immunobiology; 1996 Jan 15; 195(1):33-46. PubMed ID: 8852599 [Abstract] [Full Text] [Related]
32. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P. Am J Nephrol; 2015 Jan 15; 41(1):16-27. PubMed ID: 25612603 [Abstract] [Full Text] [Related]
33. Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls. Light J, Salomon DR, Diethelm AG, Alexander JW, Hunsicker L, Thistlethwaite R, Reinsmoen N, Stablein DM. Clin Transplant; 2002 Oct 15; 16(5):317-24. PubMed ID: 12225426 [Abstract] [Full Text] [Related]
34. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Clark G, Walsh G, Deshpande P, Koffman G. Nephrol Dial Transplant; 2002 Jul 15; 17(7):1304-9. PubMed ID: 12105256 [Abstract] [Full Text] [Related]
35. OKT3 treatment of steroid-resistant renal allograft rejection. Thistlethwaite JR, Gaber AO, Haag BW, Aronson AJ, Broelsch CE, Stuart JK, Stuart FP. Transplantation; 1987 Feb 15; 43(2):176-84. PubMed ID: 3544373 [Abstract] [Full Text] [Related]
36. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Wiseman LR, Faulds D. Drugs; 1999 Dec 15; 58(6):1029-42. PubMed ID: 10651389 [Abstract] [Full Text] [Related]
37. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ. Transplantation; 1997 Jul 27; 64(2):274-81. PubMed ID: 9256187 [Abstract] [Full Text] [Related]
38. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. Chen CC, Koenig A, Saison C, Dahdal S, Rigault G, Barba T, Taillardet M, Chartoire D, Ovize M, Morelon E, Defrance T, Thaunat O. Front Immunol; 2018 Jul 27; 9():275. PubMed ID: 29515582 [Abstract] [Full Text] [Related]
39. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers. Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A. Isr Med Assoc J; 2002 Nov 27; 4(11 Suppl):935-9. PubMed ID: 12455184 [Abstract] [Full Text] [Related]
40. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Haug CE, Colvin RB, Delmonico FL, Auchincloss H, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB. Transplantation; 1993 Apr 27; 55(4):766-72; discussion 772-3. PubMed ID: 8097341 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]